190 related articles for article (PubMed ID: 29772552)
1. PET/CT in the diagnosis and prognosis of osteosarcoma.
Zhang X; Guan Z
Front Biosci (Landmark Ed); 2018 Jun; 23(11):2157-2165. PubMed ID: 29772552
[TBL] [Abstract][Full Text] [Related]
2. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
[TBL] [Abstract][Full Text] [Related]
3. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
4. Can pretreatment
Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
[TBL] [Abstract][Full Text] [Related]
5. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
[TBL] [Abstract][Full Text] [Related]
8. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
[TBL] [Abstract][Full Text] [Related]
9. The Utility of 18FDG PET/CT Versus Bone Scan for Identification of Bone Metastases in a Pediatric Sarcoma Population and a Review of the Literature.
Tal AL; Doshi H; Parkar F; Abraham T; Love C; Ye K; Yang R; Hoang B; Loeb D; Chou A; Geller D; Moadel R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):52-58. PubMed ID: 32815877
[TBL] [Abstract][Full Text] [Related]
10. The use of fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography as an effective method for staging in dogs with primary appendicular osteosarcoma.
Crooks C; Randall E; Griffin L
Vet Radiol Ultrasound; 2021 May; 62(3):350-359. PubMed ID: 33629412
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of Magnetic Resonance Imaging and [
Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of
Liu F; Zhang Q; Zhou D; Dong J
BMC Cancer; 2019 Apr; 19(1):323. PubMed ID: 30953476
[TBL] [Abstract][Full Text] [Related]
13. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
[TBL] [Abstract][Full Text] [Related]
14. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
[TBL] [Abstract][Full Text] [Related]
15. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
[TBL] [Abstract][Full Text] [Related]
16.
Oh C; Bishop MW; Cho SY; Im HJ; Shulkin BL
J Nucl Med; 2023 Jun; 64(6):842-851. PubMed ID: 37201958
[TBL] [Abstract][Full Text] [Related]
17. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
Xu J; Li Y; Xie L; Sun X; Cai Z; Wang S; Wang Q; Sun K; Guo W
Ann Nucl Med; 2022 Jun; 36(6):553-561. PubMed ID: 35380350
[TBL] [Abstract][Full Text] [Related]
19. The relation between staging fluorine-18 fluorodeoxyglucose positron emission tomog- raphy/computed tomography metabolic parameters and tumor necrosis rate in pediatric osteosarcoma patients.
Fidan AK; Uçmak G; Demirel BB; Efetürk H; Öztürk İ; Demirtaş Şenlik S; Esen Akkaş B; Ergürhan İlhan İ
Turk J Med Sci; 2021 Jun; 51(3):1115-1122. PubMed ID: 33387988
[TBL] [Abstract][Full Text] [Related]
20. Tumor-to-background ratio to predict response to chemotherapy of osteosarcoma better than standard uptake values.
He JP; Hao Y; Li M; Wang J; Guo FJ
Orthop Surg; 2014 May; 6(2):145-53. PubMed ID: 24890297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
